The purpose of this study is to learn more about the new drug PRO1160. We want to see if it is safe and helpful for treating patients with cancer that didn't fully respond to treatment or has come back. Volunteers must have kidney cancer, throat cancer, or a type of blood cancer called non-Hodgkin lymphoma.
